GZR18
Phase 3Small molecule
GZR18 is one of 212 small molecule programs targeting Diabetes Mellitus, Type 2. It is currently in Phase 3.
8
Indications
20
Total Trials
12
Active Trials
211
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Retatrutide
Eli LillyPhase 3
GZR18
GGan & Lee Pharmaceuticals.
Phase 3
HDM1002
HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
GZR4
GGan and Lee Pharmaceuticals, USA
Phase 3
Imeglimin
PPoxel SA
Phase 3
Ganagliflozin
HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
HM11260C
Hanmi Pharmaceutical Company LimitedPhase 3
TG103
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 3
NOVOLIN R
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Overweight6 trials
Type 2 Diabetes Mellitus5 trials
Obstructive Sleep Apnea1 trial
3 more indications
Renal Impairment1 trial
Obesity and Overweight1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GZR18. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- GGan & Lee Pharmaceuticals.